Ruiz-Villaverde R, Sánchez-Cano D, Burkhardt-Pérez P
Dermatology Unit, Complejo Hospitalario de Jaén, Jaén, Spain.
J Eur Acad Dermatol Venereol. 2009 Jul;23(7):828-31. doi: 10.1111/j.1468-3083.2008.03019.x.
Basal cell carcinoma (BCC) is a malignant cutaneous neoplasm with a tendency to spread locally and with several clinical and histological subsets. We studied 82 patients with a clinical diagnosis of superficial BCC on different anatomical locations, to whom imiquimod 5% cream was administered on a low-frequency regime (three times a week for 4 weeks), and who were followed up 2 years after completion of treatment. Clinical clearance rate at 1 and 2 years were 89% and 85%, respectively. We conclude that imiquimod seems to be an appropriate therapeutic alternative for the treatment of superficial BCC in patients with associated comorbidities.
基底细胞癌（BCC）是一种恶性皮肤肿瘤，有局部扩散的倾向，且有多种临床和组织学亚型。我们研究了82例临床诊断为浅表性基底细胞癌且病变位于不同解剖部位的患者，对其采用低频率方案（每周3次，共4周）外用5%咪喹莫特乳膏进行治疗，并在治疗结束后随访2年。1年和2年时的临床清除率分别为89%和85%。我们得出结论，对于伴有合并症的浅表性基底细胞癌患者，咪喹莫特似乎是一种合适的治疗选择。
